Zuoli Pharmaceutical: Announcement on the Change of Signed Certified Public Accountants and Quality Control Reviewers
Zuoli Pharmaceutical: Report by Guojin Securities Co., Ltd. on the 2024 continuous supervision and training situation of Zhejiang Zuoli Pharmaceutical Co., Ltd.
Zuoli Pharmaceutical: Guojin Securities Co., Ltd.\'s 2024 regular on-site inspection report on Zhejiang Zuoli Pharmaceutical Co., Ltd.
Zuoli Pharmaceuticals: Investor Relations Activity Record Form for November 26, 2024
Zuoli Pharmaceutical: Record of Investor Relations Activities from November 19, 2024 to November 20, 2024
Zuoli Pharmaceutical: Record of Investor Relations Activities from October 28, 2024 to October 29, 2024
Zuoli Pharmaceutical: Announcement of Resolutions of the Third Meeting of the Eighth Board of Directors
Zuoli Pharmaceutical: 2024 Restricted Stock Incentive Plan Implementation Assessment Management Measures
Zuoli Pharmaceutical: Announcement on Open Call for Voting Rights for Independent Directors
Zuoli Pharmaceutical: Announcement of Resolutions of the Third Meeting of the Eighth Board of Supervisors
Zuoli Pharmaceutical: Legal Opinion of Shanghai Oriental Huayin Law Firm on the 2024 Employee Stock Ownership Plan of Zhejiang Zuoli Pharmaceutical Co., Ltd.
Zuli Pharmaceutical: 2024 Employee Stock Ownership Plan Management Measures
Zuoli Pharmaceutical: Record of Investor Relations Activities from September 12, 2024 to September 13, 2024
Zuoli Pharmaceuticals: Investor Relations Activity Record Form for August 29, 2024
Zhejiang Jolly Pharmaceutical: Announcement on the Progress of Providing Guarantees for the Holding Subsidiary to Apply for Credit Limits from Banks.
Zhejiang Jolly Pharmaceutical: Investor relations activity record form from August 5th to August 7th, 2024.
Zhejiang Jolly Pharmaceutical: Investor Relations Activity Record Form from July 30th, 2024 to August 1st, 2024.
Zhejiang Jolly Pharmaceutical: Special report on the collection and use of funds for the first half of 2024.
Zhejiang Jolly Pharmaceutical: Sinolink's continuous supervision and follow-up report on Zhejiang Jolly Pharmaceutical Co., Ltd. for the first half of 2024.
Zhejiang Jolly Pharmaceutical: Board of directors resolution announcement.
No Data